More on: mild hemophilia A and inhibitor development

Martin Koestenberger,B. Leschnik,Wolfgang Muntean

DOI: https://doi.org/10.1111/j.1538-7836.2004.00677.x

2004-04-01

Journal of Thrombosis and Haemostasis

Abstract:We read with interest the article by Sharathkumar et al. [1] describing inhibitor development in mild hemophilia A. In this article one of our patients is cited as developing an inhibitor after continuous infusion of factor (F) VIII [2]. We have to mention that this patient, unfortunately not stated clearly in our article, suffers from severe and not from mild hemophilia A. However, we did observe two mildly hemophilic patients who exactly fit in the pattern described by Sharathkumar et al. [1]. In 7and 15-year-old mild hemophiliacs with FVIII plasma levels of 14% and 18%, respectively, surgery due to Perthes disease and severe fracture of the ankle joint, respectively, became necessary. The first patient had been treated before with recombinant factor VIII (rFVIII) only four times since detection of mild hemophilia A while the second was previously untreated. Before surgery inhibitor screening was negative. During surgery and over the following 8 days the first patient received continuous rFVIII in a dose of 4 U kg h followed by 2 U kg h for an additional 3 days. The second patient received rFVIII during surgery and the following 9 days in a dose of 5 U kg h followed by 2 U kg h for an additional 6 days. Good recovery and satisfactory plasma levels were found. Six and 4 weeks later, respectively, the patients were admitted to hospital due to a soft tissue bleeding episode and a right elbow hemarthrosis. FVIII plasma levels were below 1 % and inhibitor test revealed a low titer inhibitor (4 BU) for the first patient, as demonstrated more frequently in this group of patients [3], and a high titer inhibitor (33 BU) for the second patient. No family history of inhibitor development, suggested to be a risk factor [4], was found in our patients. The first patient could be successfully treated with high FVIII concentrations while the second had to be treated with rFVIIa. Immune tolerance induction using a modified Bonn protocol [5] resulted in complete inhibitor suppression within 5 months in the first patient, but in the second patient repeated rFVIIa administrations were necessary due to recurrent hemorrhages during immune tolerance induction. Inhibitor suppression could finally be achieved after 15 months of treatment. As most of the patients by Sharathkumar et al. [1], our patients had multiple risk factors for developing an inhibitor. The inhibitor development occurred within the first few administrations of FVIII, known to be at higher risk for inhibitor development [6]. Our patients also had major surgery, suggested to be a situation that facilitates an antibody response against exogenous FVIII [7], and they had massive continuous infusion of FVIII. Therefore it is impossible to determine what was the reason for inhibitor development, but our cases, similar to the cases reported by Sharathkumar et al. [1], suggest that mild hemophiliacs do have a distinct risk for inhibitor development and should be closely monitored especially in situations with large FVIII exposure.